Manohursingh Runglall
Overview
Explore the profile of Manohursingh Runglall including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
1113
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Othman J, Potter N, Ivey A, Tazi Y, Papaemmanuil E, Jovanovic J, et al.
Blood
. 2024 May;
144(7):714-728.
PMID: 38691678
Although NPM1-mutated acute myeloid leukemia (AML) carries a generally favorable prognosis, many patients still relapse and die. Previous studies identified several molecular and clinical features associated with poor outcomes; however,...
2.
Othman J, Potter N, Ivey A, Jovanovic J, Runglall M, Freeman S, et al.
Blood
. 2024 Feb;
143(19):1931-1936.
PMID: 38364112
Selection of patients with NPM1-mutated acute myeloid leukemia (AML) for allogeneic transplant in first complete remission (CR1-allo) remains controversial because of a lack of robust data. Consequently, some centers consider...
3.
Loo S, Dillon R, Ivey A, Anstee N, Othman J, Tiong I, et al.
Blood
. 2022 Aug;
140(22):2407-2411.
PMID: 35960851
No abstract available.
4.
Alimam S, Villiers W, Dillon R, Simpson M, Runglall M, Smith A, et al.
Blood Adv
. 2021 Feb;
5(4):1059-1068.
PMID: 33599741
Approximately 10% to 15% of patients with essential thrombocythemia (ET) lack the common driver mutations, so-called "triple-negative" (TN) disease. We undertook a systematic approach to investigate for somatic mutations and...
5.
Christakoudi S, Runglall M, Mobillo P, Rebollo-Mesa I, Tsui T, Nova-Lamperti E, et al.
EBioMedicine
. 2020 Jul;
58:102899.
PMID: 32707447
Background: Kidney transplant recipients (KTRs) with "operational tolerance" (OT) maintain a functioning graft without immunosuppressive (IS) drugs, thus avoiding treatment complications. Nevertheless, IS drugs can influence gene-expression signatures aiming to...
6.
Tiong I, Dillon R, Ivey A, Teh T, Nguyen P, Cummings N, et al.
Br J Haematol
. 2020 May;
192(6):1026-1030.
PMID: 32458446
Based on promising results in older adults with acute myeloid leukaemia (AML), we treated patients with NPM1 measurable residual disease (MRD) using off-label venetoclax in combination with low-dose cytarabine or...
7.
Dillon R, Hills R, Freeman S, Potter N, Jovanovic J, Ivey A, et al.
Blood
. 2020 Jan;
135(9):680-688.
PMID: 31932839
Relapse remains the most common cause of treatment failure for patients with acute myeloid leukemia (AML) who undergo allogeneic stem cell transplantation (alloSCT), and carries a grave prognosis. Multiple studies...
8.
Christakoudi S, Runglall M, Chowdhury P, Hernandez-Fuentes M
EBioMedicine
. 2019 Apr;
42:42.
PMID: 30930045
No abstract available.
9.
Christakoudi S, Runglall M, Mobillo P, Tsui T, Duff C, Domingo-Vila C, et al.
EBioMedicine
. 2019 Mar;
41:571-583.
PMID: 30833191
Background: Acute T-cell mediated rejection (TCMR) is usually indicated by alteration in serum-creatinine measurements when considerable transplant damage has already occurred. There is, therefore, a need for non-invasive early detection...
10.
Christakoudi S, Runglall M, Mobillo P, Rebollo-Mesa I, Tsui T, Nova-Lamperti E, et al.
Mol Cell Endocrinol
. 2018 Feb;
473:205-216.
PMID: 29427591
Steroid conversion (HSD11B1, HSD11B2, H6PD) and receptor genes (NR3C1, NR3C2) were examined in kidney-transplant recipients with "operational tolerance" and chronic rejection (CR), independently and within the context of 88 tolerance-associated...